Hospital Universitario 12 De Octubre
Hospital Universitario 12 De Octubre is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib
Sponsor Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
- Start (EU)
- Latest update
- Estimated end
- Not reported
Induction therapy with bortezomib, melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs. carfilzomib, lenalidomide and dexamethasone (KRd) with/without daratumumab, 18 cycles, followed by consolidation and maintenance with lenalidomide and daratumumab: a phase III, multicenter, randomized clinical trial for older adult patients between 65 and 80 years old, in good general health with newly-diagnosed multiple myeloma
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes
Sponsor Pethema Fundacion
- Start (EU)
- Latest update
- Estimated end
- Not reported
Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
Sponsor Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM)
Sponsor Fundacion Pethema
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase II, Open-Label, Multicenter, Non-Randomized Study Of The Efficacy And Safety Of Enfortumab Vedotin In Combination With Pembrolizumab Previously Treated Advanced Melanoma
Sponsor Grupo Espanol Multidisciplinar De Melanoma
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN)
Sponsor Grupo Espanol De Oncologia Genitourinaria-Socug
- Start (EU)
- Latest update
- Estimated end
A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autologous peripheral blood stem cell transplantation, consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients ≤ 70 years old with smoldering multiple myeloma (SMM) with high risk of progression to symptomatic myeloma
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, refractory to lenalidomide.
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Hospital Universitario 12 De Octubre?
The 2026-10-09 snapshot links Hospital Universitario 12 De Octubre to 11 distinct CTIS trials. Recorded services include Laboratory services, Immunophenotypic study (MPFC and MRD),molecular analysis, NGS-MRD in BM, Undad de Biología Molecular-Servicio de Hematología. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Hospital Universitario 12 De Octubre?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Hospital Universitario 12 De Octubre conducted?
The linked trials record locations in 6 countries, including Spain, France, Italy, Germany, Denmark. These are trial locations, not confirmed office locations or countries where Hospital Universitario 12 De Octubre delivered services.
What can this page tell me about Hospital Universitario 12 De Octubre's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Hospital Universitario 12 De Octubre. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Hospital Universitario 12 De Octubre